How should isosorbide dinitrate be dosed and monitored in patients with chronic kidney disease (including stages 3‑5 and those on hemodialysis)?

Isosorbide Dinitrate Use in Chronic Kidney Disease

Isosorbide dinitrate can be safely used in patients with chronic kidney disease, including those on hemodialysis, without dose adjustment, as the drug undergoes primarily hepatic metabolism with minimal renal clearance. 1, 2

Pharmacokinetics in CKD

The pharmacokinetic profile of isosorbide dinitrate remains largely unchanged in renal failure:

• Plasma concentrations of isosorbide dinitrate and its active metabolites (2-mononitrate and 5-mononitrate) show no clinically significant differences between patients with and without renal failure 2, 3
• Clearance occurs primarily through hepatic denitration (exceeding hepatic blood flow, indicating extrahepatic metabolism as well), with the 5-mononitrate being the predominant metabolite (75-85%) 1
• Hemodialysis removes only approximately 0.5% of an administered dose (0.3 mg during a 5-hour session), with no measurable impact on plasma levels 4

Dosing Recommendations

Standard Dosing (Same as Non-CKD Patients)

For heart failure with reduced ejection fraction (HFrEF), particularly when combined with hydralazine:

• Initial dose: 20 mg isosorbide dinitrate three times daily (combined with 37.5 mg hydralazine) 5, 6, 5, 7
• Target dose: 40 mg isosorbide dinitrate three times daily (combined with 75 mg hydralazine) for a total daily dose of 120 mg isosorbide dinitrate 5, 6, 5, 7
• Alternative separate dosing: Start with 20-30 mg isosorbide dinitrate 3-4 times daily, titrating up to a maximum of 120 mg total daily in divided doses 5, 6, 7

Dosing Strategy to Prevent Tolerance

A critical consideration is maintaining a daily dose-free interval of at least 14 hours to prevent nitrate tolerance 1:

• Administer doses 2-3 times daily with the last dose given early enough to allow a 14-hour nitrate-free period 1
• Continuous 24-hour plasma levels result in refractory tolerance, limiting efficacy to approximately 12 hours of anti-anginal effect per day 1

Clinical Indications in CKD

Primary Indication: HFrEF with ACE Inhibitor/ARB Intolerance

The combination of hydralazine and isosorbide dinitrate is specifically recommended for patients with HFrEF who cannot tolerate ACE inhibitors or ARBs due to:

• Renal insufficiency 8, 5
• Hyperkalemia 8
• Hypotension 5
• Drug intolerance 5

This represents a Class IIa recommendation (can be useful to reduce morbidity or mortality) with Level of Evidence B 5

Additional Indication: African American Patients with HFrEF

For self-identified African American patients with HFrEF, hydralazine-isosorbide dinitrate should be added to standard therapy (ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists) as it provides significant mortality benefit 8, 5:

• This is a Class I recommendation (Strong Recommendation, Moderate-Quality Evidence) for Black patients 8
• The combination demonstrated a 43% relative risk reduction in mortality 5, 7

Monitoring Requirements

Blood Pressure Monitoring

Monitor blood pressure after initiation and during titration 9:

• Frequent adverse effects include headache, dizziness, and hypotension 5
• Slower titration may enhance tolerance to therapy 5

Renal Function Monitoring

While isosorbide dinitrate itself does not require renal dose adjustment, patients with CKD require general monitoring:

• Assess eGFR, electrolytes, and concomitant medications regularly, particularly when using multiple cardiovascular agents 10
• In patients with severe renal dysfunction (CrCl <30 mL/min), higher doses or combination diuretic agents may be needed for congestion management 8

Special Consideration: Contrast-Induced Nephropathy Prevention

Emerging evidence suggests that adequate hydration combined with isosorbide dinitrate may reduce contrast-induced nephropathy risk in patients with both CKD and congestive heart failure:

• Continuous intravenous isosorbide dinitrate combined with isotonic saline at 1.5 mL/kg/h during perioperative coronary procedures reduced CIN incidence (12.8% vs 21.2%, p=0.018) without increasing acute heart failure risk 11

Outcomes in Dialysis Patients

Retrospective data from the United States Renal Data System demonstrates potential cardiovascular benefit in maintenance dialysis patients with heart failure:

• All-cause mortality was lower with hydralazine-isosorbide dinitrate use (16.0 vs 27.9 events/100 patient-years), with a weighted hazard ratio of 0.48 (95% CI 0.43-0.54) 12
• Cardiovascular death and sudden cardiac death were reduced (HR 0.62 for both outcomes) 12
• However, heart failure admissions and myocardial infarction were paradoxically more frequent, possibly reflecting confounding by indication 12

Important Caveats

Adherence Challenges

Adherence to the hydralazine-isosorbide dinitrate combination is generally poor due to:

• Large number of tablets required (up to 6 tablets daily at target dose) 5
• Frequent dosing schedule (three times daily) 5
• High incidence of adverse reactions (headache, dizziness, gastrointestinal complaints) 5

Not a Substitute for Standard Therapy

The combination should not be substituted for ACE inhibitor or ARB therapy in patients tolerating these agents without difficulty 5:

• It should only be used when ACE inhibitors/ARBs are contraindicated or not tolerated 5
• It should not be used in patients with no prior use of standard neurohumoral antagonist therapy 5

Medication Review at Transitions of Care

Perform thorough medication review periodically and at transitions of care, with clear documentation of when to restart medications if temporarily discontinued during acute illness or procedures 10